LIPO (Lipella Pharmaceuticals) EBIT per Share: $-2.39 (TTM As of Sep. 2025)


What is Lipella Pharmaceuticals EBIT per Share?

Lipella Pharmaceuticals LIPO +97.76% EBIT per Share is $-2.39 as of Sep. 2025. The stock has 1 warning sign investors should review. Among 1,180 Biotechnology companies, Lipella Pharmaceuticals ranks worse than 87.88% on this metric.

Lipella Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2025 was $-0.28. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $-2.39.

During the past 3 years, the average EBIT per Share Growth Rate was -22.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lipella Pharmaceuticals's EBIT per Share or its related term are showing as below:

LIPO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -331.1   Med: -176.55   Max: -22
Current: -22

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Lipella Pharmaceuticals was -22.00% per year. The lowest was -331.10% per year. And the median was -176.55% per year.

LIPO's 3-Year EBIT Growth Rate is ranked worse than
87.88% of 1180 companies
in the Biotechnology industry
Industry Median: 15.55 vs LIPO: -22.00

Lipella Pharmaceuticals's EBIT for the three months ended in Sep. 2025 was $-1.27 Mil.

Lipella Pharmaceuticals  (OTCPK:LIPO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lipella Pharmaceuticals EBIT per Share Related Terms

Lipella Pharmaceuticals EBIT per Share Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals EBIT per Share Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
-0.08 -2.59 -5.09 -6.14 -4.79

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.30 -1.15 -0.65 -0.32 -0.28

Lipella Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lipella Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-5.016/1.048
=-4.79

Lipella Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2025 is calculated as

EBIT per Share(Q: Sep. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.274/4.549
=-0.28

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-2.39 mean?
Lipella Pharmaceuticals (LIPO) has a EBIT per Share of $-2.39 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lipella Pharmaceuticals and its competitors. According to the industry distribution chart, Lipella Pharmaceuticals ranks #1037 out of 1180 companies in the Biotechnology industry, placing it in the top 87.9%.
Is Lipella Pharmaceuticals' EBIT per Share too high?
Lipella Pharmaceuticals' current EBIT per Share is $-2.39. Based on the distribution chart, Lipella Pharmaceuticals ranks #1037 out of 1180 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lipella Pharmaceuticals' EBIT per Share compare to IOBTQ and WINT?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #1037 out of 1180 companies for EBIT per Share. This places Lipella Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lipella Pharmaceuticals and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipella Pharmaceuticals's current EBIT per Share is $-2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.68, compared to a current price of $0.11 — trading 98.7% below its estimated fair value. The current EBIT per Share is $-2.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current EBIT per Share is $-2.39 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.